Physician profile

Benjamin Bonte

Physical Medicine & Rehabilitation · Purchase, NY

NPI 1972846509

$18,134.84

in general payments reported to CMS, 2019-2025

41 companies · $4,508 in 2025

The $4,508 reported for 2025 was more than what 97% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$9,965.66
Travel and Lodging$341.24

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Nevro Corp. $5,011.50 2019-2024 Senza
Abbvie INC. $3,713.29 2021-2025 Botox, Ubrelvy, Qulipta
Boston Scientific Corporation $1,638.35 2019-2025 Wavewriter Alpha Prime 16, Intracept
Abbott Laboratories $1,281.80 2021-2025 Proclaim, Axium, Eterna
Medtronic, INC. $1,221.89 2021-2025 Intellis Adaptivestim, Mazor X System
Lundbeck LLC $1,084.97 2020-2025 Vyepti
Pfizer INC. $643.13 2023-2025
Saluda Medical Americas, INC. $586.90 2025 Evoke
Si-Bone, INC. $488.89 2023-2025
Vertos Medical, INC. $263.19 2019-2024 Mild Device Kit
Merz Pharmaceuticals, LLC $209.50 2022-2025 Xeomin
Medtronic USA, INC. $191.16 2019
Bioventus LLC $171.64 2019-2023 Durolane
Curonix LLC $161.21 2024-2025 Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Biohaven Pharmaceutical Holding Company LTD. $159.06 2022
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $125.12 2020-2021
Biohaven Pharmaceuticals, INC. $110.90 2020-2021
Catalyst Pharmaceuticals, INC. $105.96 2020-2021
Alexion Pharmaceuticals, INC. $96.14 2019-2021
Globus Medical, INC. $90.52 2025 Senza
Axsome Therapeutics, INC. $82.60 2025 Symbravo
Ferring Pharmaceuticals INC. $77.18 2022-2025 Euflexxa
Kowa Pharmaceuticals America, INC. $73.01 2022-2023 Seglentis
Amgen INC. $64.25 2021
Vertex Pharmaceuticals Incorporated $57.95 2025
Horizon Therapeutics Plc $53.93 2019-2020
Collegium Pharmaceutical, INC. $52.14 2020-2021
Redhill Biopharma INC. $45.60 2020-2021
Organogenesis INC. $38.31 2023 Puraply
Depuy Synthes Sales INC. $31.53 2021
Azurity Pharmaceuticals, INC. $29.69 2025 Horizant
Grt US Holding, INC. $24.93 2022
Allergan, INC. $24.50 2021
Almatica Pharma LLC $22.63 2021
Nalu Medical, INC. $21.58 2024 Nalu Neurostimulation System
Spinal Simplicity, LLC $21.14 2024 Ha Minuteman G3-R
Scilex Pharmaceuticals INC. $14.50 2023 Ztlido
International Rehabilitative Sciences, INC $14.27 2025 Rs-4i Plus With Intersperse
Lilly USA, LLC $13.32 2023 Emgality
Astrazeneca Pharmaceuticals LP $11.72 2020
Spr Therapeutics, INC $4.94 2023 Sprint Pns System

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Benjamin Bonte

$18,134.84

in general payments reported 2019-2025

Years
2019-2025
Top company
Nevro Corp.
Context
The $4,508 reported for 2025 was more than what 97% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).

https://glasscript.com/doctor/561606/benjamin-bonte

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.